A Few Companies and Countries Are Reshaping Mexico’s Finished-Dose Pharma Imports

Before looking at any specific therapeutic segment in Mexico, one structural fact stands out immediately: pharma imports are overwhelmingly dominated by finished-dose medicaments rather than non-retail medicaments.

Across 2020–2025, monthly imports of Finished-Dose Medicaments consistently operated at a much larger scale than Non-Retail Medicaments. While non-retail medicaments mostly moved in a band of roughly US$5 million to US$19 million per month, finished-dose medicaments generally ranged from around US$190 million to more than US$650 million.

That gap remained fully intact at the start of 2026. In January 2026, Mexico imported US$559.8 million in finished-dose medicaments versus US$7.9 million in non-retail medicaments. In February 2026, the figures were US$580.3 million and US$6.2 million, respectively.

That matters because it shows Mexico’s pharma trade structure is shaped far more by finished-product supply and commercialization flows than by bulk or non-retail medicaments alone. For data and strategy teams, that makes the finished-dose universe the more relevant starting point for external intelligence on market structure, source dependence, and competitive positioning.

At aggregate level, the finished-dose market is already large enough to justify attention. But the more useful signal appears when the category is broken down internally.

Using a simplified grouping, three buckets stand out:

From 2020 to 2025, Other Finished-Dose Medicaments remained the largest bucket, growing from US$2.14 billion to US$3.94 billion. But its relative weight stopped strengthening. After representing 70.98% of the selected finished-dose universe in 2024, it fell to 64.23% in 2025.

By contrast, Other Hormone-Related Finished-Dose Medicaments accelerated sharply. This bucket rose from US$285 million in 2020 to US$1.21 billion in 2025, with an especially strong jump in the latest year.

In 2025 alone, this segment grew 76.73%, far outpacing both the broader residual bucket and the rest of the finished-dose universe. Its share climbed from 12.23% in 2024 to 19.69% in 2025.

The implication is clear:

Mexico’s finished-dose pharma imports are not simply expanding — they are being reweighted toward a more specific and more concentrated hormone-related subcategory.

One possible interpretation would be that this reflects general inflation or a broad uplift across all finished-dose products. The importer data suggests otherwise.

From 2020 to 2025, the leading importers of Other Hormone-Related Finished-Dose Medicaments were:

This means that in 2025:

That is not a broad-based market expansion. It is a highly concentrated surge led by a small number of multinational pharma players.

The multi-year trend points in the same direction. From 2020 to 2025, this hormone-related finished-dose segment increased by roughly US$923 million. Of that increase:

Together, those two companies explain most of the category’s expansion over the period.

The 2025 inflection was especially notable. Eli Lilly moved from US$18 million in 2024 to US$286 million in 2025, making the latest year look less like a continuation of trend and more like a major reweighting event inside the category.

The origin breakdown tells the same story from a different angle.

From 2020 to 2025, the top countries of origin for Other Hormone-Related Finished-Dose Medicaments were:

This means:

That is a very high level of origin concentration.

More importantly, the 2024–2025 increase was overwhelmingly driven by just two countries:

Together, those two countries accounted for essentially all of the category’s net increase in 2025.

So the picture is consistent across both dimensions:

The rise in hormone-related finished-dose medicaments is being driven by a tightly concentrated importer-origin configuration, not by a broad-based expansion across companies and countries.

The visual confirms that the category did not simply grow. It became more concentrated around a narrower importer-origin architecture.

In 2020, the flow map still looked relatively diversified:

By 2025, the configuration is much tighter:

Most market commentary stops at “pharma imports are rising.” That is not enough.

A more useful external-intelligence question is:

This is where transaction-level trade data becomes strategically useful.

In this case, the evidence suggests that Mexico’s finished-dose pharma imports are becoming less residual and more concentrated in specific high-growth subcategories. The rise of Other Hormone-Related Finished-Dose Medicaments is not simply a matter of scale. It is also a matter of who is driving growth, where products are coming from, and how dependent the market may be on a narrow supply architecture.

For CDOs and strategy teams, this kind of analysis can support:

Mexico’s pharma import structure is dominated by Finished-Dose Medicaments, not Non-Retail Medicaments.

Inside that finished-dose universe, the most important recent shift is not general growth in Other Finished-Dose Medicaments, but the rapid rise of Other Hormone-Related Finished-Dose Medicaments.

That shift is being driven by:

For external market intelligence, that is exactly the type of pattern worth monitoring.

If your team needs a clearer view of how specific therapeutic categories are evolving in Mexico — and which companies and countries are driving that change — I can develop a custom external-data analysis tailored to your portfolio, competitors, sourcing exposure, or category-monitoring priorities.

This work can be expanded into:

If this is relevant to your team, contact me to discuss a tailored research project for Mexico’s pharma market.